About Atypical chemokine receptor 3
Atypical chemokine receptor 3 (ACKR3) is a protein
from Homo sapiens identified by UniProt accession
P25106, 362 residues long.
MolForge cross-references it against 0 known binders and
618 disease associations.
Target properties
| Protein name | Atypical chemokine receptor 3 |
| UniProt accession | P25106 |
| Gene | ACKR3 |
| Organism | Homo sapiens |
| Length | 362 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (618)
Diseases linked to this target (Open Targets).
- oculomotor-abducens synkinesis · score 0.45
- neuroimaging measurement · score 0.44
- cortical surface area measurement · score 0.43
- cutaneous melanoma · score 0.37
- pancreatic neoplasm · score 0.37
- colon adenocarcinoma · score 0.37
- colorectal adenocarcinoma · score 0.37
- Endometrial Endometrioid Adenocarcinoma · score 0.37
- hepatocellular carcinoma · score 0.30
- cortical thickness · score 0.30
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P25106-F1 | alphafold | PREDICTED | 82.46 | — |
Amino-acid sequence (362 residues)
MDLHLFDYSE PGNFSDISWP CNSSDCIVVD TVMCPNMPNK SVLLYTLSFI YIFIFVIGMI ANSVVVWVNI QAKTTGYDTH CYILNLAIAD LWVVLTIPVW VVSLVQHNQW PMGELTCKVT HLIFSINLFG SIFFLTCMSV DRYLSITYFT NTPSSRKKMV RRVVCILVWL LAFCVSLPDT YYLKTVTSAS NNETYCRSFY PEHSIKEWLI GMELVSVVLG FAVPFSIIAV FYFLLARAIS ASSDQEKHSS RKIIFSYVVV FLVCWLPYHV AVLLDIFSIL HYIPFTCRLE HALFTALHVT QCLSLVHCCV NPVLYSFINR NYRYELMKAF IFKYSAKTGL TKLIDASRVS ETEYSALEQS TK
Explore Atypical chemokine receptor 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets